Literature DB >> 21080229

Haematopoietic stem cell transplantation does not retard disease progression in the psycho-cognitive variant of late-onset metachromatic leukodystrophy.

Nicholas J Smith1, Robert E Marcus, Barbara J Sahakian, Narinder Kapur, Timothy M Cox.   

Abstract

Haematopoietic stem cell transplantation has an unproven role in the management of late-onset metachromatic leukodystrophy: theoretically justified through the engraftment of enzyme-replete haematopoietic progenitors and restoration of capacity for sulphatide catabolism in neural tissue through enzyme recapture, the long-term outcome is unknown. The rarity of the psycho-cognitive variant and slow progression of late-onset disease impairs evaluation of treatment. We report detailed clinical and neuropsychological assessments after haematopoietic stem-cell transplantation in a patient with a late-onset psycho-cognitive form of metachromatic leukodystrophy. Cognitive decline, indistinguishable from the natural course of the disease, was serially documented over 11 years despite complete donor chimaerism and correction of leukocyte arylsulphatase A to wild type values; subtle motor deterioration was similarly noted and progressive cerebral volume loss was evident upon magnetic resonance imaging. Sensory nerve conduction deteriorated 17 months post-transplantation with apparent stabilisation at 11-year review. Haematopoietic stem-cell transplantation was ineffective for this rare attenuated variant of metachromatic leukodystrophy. In the few patients identified pre-symptomatically or with early-phase disease, clear recommendations are lacking; when transplantation is considered, umbilical cord blood grafts from enzyme-replete donors with adjunctive mesenchymal stem cell infusions from the same source may be preferable. Improved outcomes will depend on enhanced awareness and early diagnosis of the disease, so that promising interventions such as genetically modified, autologous stem cell transplantation have the best opportunity of success.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080229     DOI: 10.1007/s10545-010-9240-1

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  21 in total

1.  Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center.

Authors:  Olle Ringdén; Mats Remberger; Britt-Marie Svahn; Lisbeth Barkholt; Jonas Mattsson; Johan Aschan; Katarina Le Blanc; Britt Gustafsson; Zuzana Hassan; Brigitta Omazic; Petter Svenberg; Göran Solders; Ulrika von Döbeln; Jacek Winiarski; Per Ljungman; Gunilla Malm
Journal:  Transplantation       Date:  2006-03-15       Impact factor: 4.939

2.  Long-term stabilization after bone marrow transplantation in juvenile metachromatic leukodystrophy.

Authors:  D Kidd; J Nelson; F Jones; H Dusoir; I Wallace; S McKinstry; V Patterson
Journal:  Arch Neurol       Date:  1998-01

3.  Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation.

Authors:  P M Hoogerbrugge; O F Brouwer; P Bordigoni; O Ringden; P Kapaun; J J Ortega; A O'Meara; G Cornu; G Souillet; D Frappaz
Journal:  Lancet       Date:  1995-06-03       Impact factor: 79.321

4.  Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).

Authors:  O N Koç; J Day; M Nieder; S L Gerson; H M Lazarus; W Krivit
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

5.  Stabilization of juvenile metachromatic leukodystrophy after bone marrow transplantation: a 13-year follow-up.

Authors:  Maria Görg; Wanja Wilck; Barbara Granitzny; Anne Suerken; Zoltan Lukacs; Xiaoqi Ding; Michael Schulte-Markwort; Alfried Kohlschütter
Journal:  J Child Neurol       Date:  2007-09       Impact factor: 1.987

6.  Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy.

Authors:  G Solders; G Celsing; L Hagenfeldt; P Ljungman; B Isberg; O Ringdén
Journal:  Bone Marrow Transplant       Date:  1998-12       Impact factor: 5.483

7.  Late juvenile metachromatic leukodystrophy treated with bone marrow transplantation; a 4-year follow-up study.

Authors:  C Navarro; J M Fernández; C Domínguez; C Fachal; M Alvarez
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

8.  Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts.

Authors:  M T Porter; A L Fluharty; H Kihara
Journal:  Science       Date:  1971-06-18       Impact factor: 47.728

9.  Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy.

Authors:  Tyler Mark Pierson; Carsten G Bonnemann; Richard S Finkel; Nancy Bunin; Gihan I Tennekoon
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

Review 10.  Enzyme, cell and gene-based therapies for metachromatic leukodystrophy.

Authors:  C Sevin; P Aubourg; N Cartier
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more
  4 in total

Review 1.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 2.  Development and clinical translation of ex vivo gene therapy.

Authors:  Xiaomo Wu; Xiaorong He; Fahui Liu; Xiaochang Jiang; Ping Wang; Jinyan Zhang; Ju Jiang
Journal:  Comput Struct Biotechnol J       Date:  2022-06-11       Impact factor: 6.155

Review 3.  Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective.

Authors:  Shanice Beerepoot; Stefan Nierkens; Jaap Jan Boelens; Caroline Lindemans; Marianna Bugiani; Nicole I Wolf
Journal:  Orphanet J Rare Dis       Date:  2019-11-04       Impact factor: 4.123

4.  Allogenic hematopoietic stem cell transplantation in two siblings with adult metachromatic leukodystrophy and a systematic literature review.

Authors:  Cecilie Videbæk; Jette Stokholm; Henrik Sengeløv; Lone U Fjeldborg; Vibeke Andrée Larsen; Christian Krarup; Jørgen E Nielsen; Sabine Grønborg
Journal:  JIMD Rep       Date:  2021-05-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.